Cancer is a genomic disease and there has been extraordinary progress defining mutations that guide optimal therapy. But most patients are still not deriving the benefit of molecular markers or tumor sequencing https://
nejm.org/doi/full/10.10
56/NEJMp2210638?query=WB&cid=NEJMWeekendBriefing,December3,2022DM1731667_NEJM_Subscriber&bid=1294414605
… @NEJM today @rschilsky

→ View original post on X — @erictopol,